Evommune, Inc.
Evommune, Inc. (EVMN): 5 pipeline candidates · ~22 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
22.4 months
D/E 0.06 · 0% dilution
Lead: Phase 2
5 candidates
N/A
0 buys · 6 sells (180d)
A transparent, data-derived signal for Evommune, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$727.8M
Cash
$49.7M
Quarterly Burn
$27.5M
Runway
22.4 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| evo301 | Phase 2 |
| evo756 | Phase 2 |
| oral evo756 | Phase 2 |
| oral evo756 300 mg qd | Phase 2 |
| oral evo756 50 mg bid | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$751.9M
| Holder | Shares | Value |
|---|---|---|
| eqt fund management s.a r.l. | 4,929,633 | $113.3M |
| ra capital management, l.p. | 3,494,638 | $80.3M |
| pivotal bioventure partners investment advisor llc | 1,926,943 | $44.3M |
| andera partners | 1,897,362 | $43.6M |
| janus henderson group plc | 1,793,400 | $41.2M |
| rtw investments, lp | 1,502,235 | $34.5M |
| mpm bioimpact llc | 1,455,863 | $33.5M |
| nan fung group holdings ltd | 1,441,032 | $33.1M |
| eventide asset management, llc | 1,209,129 | $27.8M |
| vanguard capital management llc | 910,102 | $20.9M |
Showing top 10 of 82 institutional holders of Evommune, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Evommune, Inc.'s pipeline?
Evommune, Inc. (EVMN) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Evommune, Inc.'s lead drug candidate?
Evommune, Inc.'s most advanced tracked candidate is evo301 (Phase 2) for Atopic Dermatitis (AD).
What is Evommune, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Evommune, Inc. has approximately 22.4 months of cash runway.
What is Evommune, Inc.'s market capitalization?
Evommune, Inc.'s market capitalization is approximately $727.8M.
Who is the CEO of Evommune, Inc.?
Mr. Luis C. Pena is the chief executive officer of Evommune, Inc. (EVMN).
Get the full picture on Evommune, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.